<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erythema induratum (nodular vasculitis)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erythema induratum (nodular vasculitis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Erythema induratum (nodular vasculitis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maxwell A Fung, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H318691756"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Erythema induratum (EI) is an uncommon inflammatory disorder with alterations centered upon the subcutaneous fat tissue (panniculitis). The term "EI" was first proposed by Ernest Bazin in the mid-19<sup>th</sup> century, who recognized the association of the distinctive clinical and histologic changes with tuberculosis (TB) [<a href="#rid1">1,2</a>]. Subsequently, it was recognized that not all cases are associated with TB.</p><p>The three clinical subsets of EI are:</p><p class="bulletIndent1"><span class="glyph">●</span>TB-associated EI </p><p class="bulletIndent1"><span class="glyph">●</span>EI associated with other diseases or drugs</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic EI</p><p></p><p>EI most often occurs in adult females and is characterized by erythematous, tender, variably ulcerated subcutaneous nodules, classically arising on the posterior lower legs  (<a class="graphic graphic_picture graphicRef76526 graphicRef64335 graphicRef53596 graphicRef110672" href="/z/d/graphic/76526.html" rel="external">picture 1A-D</a>). Histologically, EI is a mostly lobular panniculitis associated with necrosis and a mixed granulomatous infiltrate with vasculitis  (<a class="graphic graphic_picture graphicRef110673" href="/z/d/graphic/110673.html" rel="external">picture 2</a>).</p><p>Treatment of the associated underlying disease can lead to resolution of EI and is the mainstay of treatment. Efficacy data for other treatments are limited. </p><p>The clinical features, diagnosis, and management of EI are reviewed in this topic review  (<a class="graphic graphic_algorithm graphicRef109753" href="/z/d/graphic/109753.html" rel="external">algorithm 1</a>). Other cutaneous disorders associated with TB and other forms of panniculitis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis"</a>.)</p><p class="headingAnchor" id="H1984886814"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>EI is closely related to or synonymous with "nodular vasculitis" (NV). Usage of the terms EI and NV varies worldwide, with many authorities using these terms interchangeably. Historically, EI has been regarded as the subset of NV that is associated with tuberculosis (TB). Some clinicians, including the authors who first coined the term NV in 1945, reserve the term EI for TB-associated cases and NV for non-TB-associated cases of panniculitis exhibiting identical histopathologic features [<a href="#rid3">3</a>]. TB-associated cases are classified as one of the true forms of "tuberculid." (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis", section on 'Tuberculids'</a>.)</p><p>The term EI itself is also subject to variation. Historically, "EI of Bazin" has been used to refer to TB-associated EI, in contrast to "EI of Whitfield," which recognizes non-TB-associated cases. </p><p>For the purposes of this topic review, the terms EI and NV will be regarded as interchangeable and without requirement to be used in conjunction with the names Bazin or Whitfield. </p><p class="headingAnchor" id="H2036079351"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>EI is uncommon, although incidence and prevalence are unknown. The primary demographic for EI is adult females [<a href="#rid4">4</a>]. Both tuberculosis (TB)-associated and non-TB-associated variants of EI appear to be more common in females than in males. EI may be the most common cutaneous manifestation of TB in Brazil, Japan, mainland China, and Hong Kong [<a href="#rid5">5-7</a>].</p><p>The age range for EI is wide. In one of the largest series (86 patients with EI), the median age was 56 years (range 23 to 81 years) [<a href="#rid8">8</a>]. In a separate series of 32 patients with TB-associated EI, the mean age of presentation was 37 years (range 13 to 66 years) [<a href="#rid9">9</a>]. In addition, there are case reports of TB-associated EI in young children [<a href="#rid10">10-12</a>]. </p><p>Data are insufficient for definitive conclusions about racial or ethnic predilections in EI, but cases have been reported from North America [<a href="#rid4">4,13</a>], Central America [<a href="#rid6">6</a>], South America [<a href="#rid14">14</a>], Europe [<a href="#rid8">8</a>], Asia [<a href="#rid9">9</a>], the Middle East [<a href="#rid15">15,16</a>], Africa [<a href="#rid17">17</a>], and Australia [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H4222225404"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of EI is poorly understood. Similar to other forms of noninfectious panniculitis, EI is regarded as an immune-mediated hypersensitivity reaction. In EI, the histologic reaction pattern is specifically characterized by a mixed granulomatous inflammatory process triggered by <em>Mycobacterium tuberculosis</em> or other antigens that induce similar or identical clinicopathologic features (see <a class="local">'Associated disorders'</a> below). In addition, given that vasculitis is a histologic hallmark, endothelial antigens may be the target of cell-mediated cytotoxicity. Based upon these concepts, EI has been characterized as having features of both type III (immune-complex vasculitis) and type IV (delayed) hypersensitivity. (See <a class="local">'Histopathology'</a> below.)</p><p class="headingAnchor" id="H1499466760"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>EI is typically confined to the lower legs, classically the posterior leg (calf) and/or lateral leg, and may be unilateral or bilateral  (<a class="graphic graphic_picture graphicRef76526 graphicRef64335 graphicRef53596 graphicRef110672" href="/z/d/graphic/76526.html" rel="external">picture 1A-D</a>). Atypical distributions can occur, including a predilection for the shins as described in a series of 25 patients in Singapore [<a href="#rid19">19</a>]. In addition, EI occasionally arises on the thighs or upper extremities, and rare truncal, facial, or disseminated involvement has been reported [<a href="#rid20">20,21</a>]. </p><p>The earliest clinical manifestation of EI is one or more erythematous subcutaneous nodule(s). Individual lesions are typically no greater than 2 cm in diameter [<a href="#rid4">4,22</a>]. Nodules may or may not be scaly. Tenderness typically is present. Pain is variable but usually not excruciating, if present. </p><p>With sufficient severity or disease progression, ulceration is characteristic. Healed lesions may leave scars and, rarely, lipoatrophy [<a href="#rid23">23</a>].</p><p>Patients with EI typically lack constitutional symptoms with the exception of those related to underlying disease. Associated peripheral neuropathy has been reported [<a href="#rid24">24,25</a>]. </p><p class="headingAnchor" id="H319243224"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>EI may be subclassified into three clinical subsets:</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis (TB)-associated EI</p><p class="bulletIndent1"><span class="glyph">●</span>EI associated with other diseases or drugs</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic EI</p><p></p><p>These subsets cannot be distinguished by clinical morphology or histopathology. </p><p>Based upon published reports, latent or active TB is the most commonly reported identifiable cause of EI. In a review of 26 patients diagnosed with EI between 1966 and 1986 in England, all patients had a positive <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> [<a href="#rid4">4</a>]. In a Spanish retrospective study that included 65 patients given a histologic diagnosis of EI between 1976 and 1994, 89 percent had a positive tuberculin skin test [<a href="#rid26">26</a>]. A Singaporean retrospective study of 25 patients diagnosed with EI between 1989 and 1995 found active pulmonary tuberculosis in 28 percent [<a href="#rid19">19</a>]. </p><p>EI may present in association with other forms of tuberculid, most commonly with papulonecrotic tuberculid [<a href="#rid27">27-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis", section on 'Tuberculids'</a>.)</p><p>Disease associations other than TB are much less common but have been documented in case reports. Examples include: </p><p class="bulletIndent1"><span class="glyph">●</span>Superficial thrombophlebitis [<a href="#rid8">8,30</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune diseases (systemic lupus erythematosus [<a href="#rid31">31</a>], rheumatoid arthritis [<a href="#rid8">8,30</a>], hypothyroidism [<a href="#rid8">8,30</a>], Addison disease [<a href="#rid32">32</a>]) and Takayasu arteritis [<a href="#rid33">33</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory bowel disease (Crohn disease [<a href="#rid34">34</a>], ulcerative colitis [<a href="#rid35">35</a>]), including development of EI in the setting of <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a> therapy for Crohn disease [<a href="#rid36">36,37</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic disorders (chronic lymphocytic leukemia, antiphospholipid antibodies [<a href="#rid38">38</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung cancer [<a href="#rid39">39</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viral infections (hepatitis C virus [<a href="#rid40">40</a>], hepatitis C virus in association with red fingers syndrome [<a href="#rid41">41</a>], hepatitis B virus [<a href="#rid8">8</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial infections (<em>Nocardia</em>, <em>Pseudomonas</em>, <em>Fusarium</em>, <em>Chlamydophila pneumoniae</em> [<a href="#rid42">42</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycobacterial infections (<em>Mycobacterium chelonae</em> [<a href="#rid43">43</a>], <em>Mycobacterium avium</em> [<a href="#rid44">44</a>], and <em>Mycobacterium monacense</em> [<a href="#rid45">45</a>])</p><p></p><p>Medication associations described in case reports include <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid46">46</a>], <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid47">47</a>], intravesical Bacillus Calmette-Guérin immunotherapy [<a href="#rid48">48</a>], and <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> [<a href="#rid49">49</a>]. In addition, EI has occurred in association with new-onset tuberculous lymphadenitis in a patient treated with <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> for rheumatoid arthritis [<a href="#rid50">50</a>]. Recurrence of EI during chemotherapy for breast cancer also is reported [<a href="#rid51">51</a>].</p><p>A minority of cases of EI have no plausible cause or association (idiopathic EI).</p><p class="headingAnchor" id="H4225310066"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Typical pathology findings in EI include panniculitis and vasculitis  (<a class="graphic graphic_picture graphicRef110673" href="/z/d/graphic/110673.html" rel="external">picture 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panniculitis </strong>– At scanning magnification, the inflammatory infiltrate exhibits a predominantly lobular pattern. The inflammatory infiltrate is "mixed," typically containing lymphocytes, plasma cells, histiocytes forming granulomas, neutrophils, and eosinophils. Extravascular foci of fibrinoid necrosis are typically present, although these may represent nondiagnostic sections through centrilobular venules affected and possibly obscured by venulitis (vasculitis involving venules). Neutrophil-rich granulomas typify early lesions, whereas histiocytes may predominate in later stages [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculitis </strong>– The vasculitis may involve a variety of vessel types including arteries, arterioles, veins, and venules in the subcutaneous septa and/or lobules. In the largest series of histologically confirmed cases of EI (101 biopsies from 86 patients), small centrilobular venules were most commonly involved, with less frequent involvement of septal veins and/or septal arteries [<a href="#rid8">8</a>]. Vasculitis is not always seen in specimens of EI. In the series, vasculitis was not identified in 10 percent of biopsies [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1">The associated infiltrate exhibits leukocytoclasis and may appear neutrophilic or lymphocytic. The appearance of lymphocytic vasculitis in EI has been interpreted as a late stage of a primarily neutrophilic vasculitis. Granulomatous vasculitis, a histologic hallmark of nodular tuberculid that also occurs in EI, may represent an even later stage of the vasculitic process [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent1">Ulceration in EI is attributed to ischemic necrosis secondary to occluding vasculitis. The presence of ulceration does not clearly correlate with a particular type of vessel involvement.</p><p></p><p class="headingAnchor" id="H774836499"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of EI is made based upon a composite assessment of the clinical and skin biopsy findings combined with negative test results for lesional infection  (<a class="graphic graphic_algorithm graphicRef109753" href="/z/d/graphic/109753.html" rel="external">algorithm 1</a>). </p><p>In sum, key features that support a diagnosis of EI are:</p><p class="bulletIndent1"><span class="glyph">●</span>Erythematous, tender nodules on the lower legs, particularly the calf (with or without ulceration)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin biopsy demonstrating:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Predominantly lobular panniculitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed inflammatory infiltrate containing lymphocytes, plasma cells, histiocytes forming granulomas, neutrophils, and eosinophils</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasculitis (examination of multiple sections may be required)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Negative stains and cultures for bacteria, mycobacteria, and fungi</p><p></p><p>A diagnosis of EI should be followed by an evaluation for tuberculosis. (See <a class="local">'Additional studies'</a> below.)</p><p class="headingAnchor" id="H2895530901"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination is focused on the lower extremities since involvement of other sites is uncommon. Involvement of other body sites does not rule out EI but should prompt consideration of other disorders. (See <a class="local">'Clinical presentation'</a> above.)</p><p class="headingAnchor" id="H1770813235"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A biopsy is required to confirm the diagnosis. The biopsy type can be critical. Small biopsies or superficial punch biopsies are more likely to render the specimen nondiagnostic or misinterpreted. Ideally, an incisional biopsy or full-thickness punch biopsy should be taken from lesional skin. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a>.)</p><p>In addition, stains and cultures for bacteria, mycobacteria, and fungi should be obtained. By definition, lesional histochemical stains and lesional cultures are negative for pathogens in EI. </p><p class="headingAnchor" id="H4073599014"><span class="h1">ADDITIONAL STUDIES</span><span class="headingEndMark"> — </span>Patients with EI should be evaluated for underlying disease, particularly tuberculosis (TB). An appropriate work-up for patients without a known history of TB includes:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">Tuberculin skin test</a> or interferon gamma release assay [<a href="#rid13">13,55,56</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Review of systems</p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph</p><p></p><p>If available, polymerase chain reaction (PCR) for <em>M. tuberculosis</em> from lesional formalin-fixed tissue can be used to support an association of EI with TB [<a href="#rid13">13</a>]. However, the diagnostic sensitivity is variable and likely affected by technical factors as well as the prevalence of EI and TB in the population. In a retrospective study from the United States, PCR-based testing of biopsy specimens of EI for TB was positive in 5 of 20 patients (25 percent) with positive tuberculin skin tests and characteristic lesions that responded to antituberculous treatment [<a href="#rid57">57</a>]. In a larger retrospective study from Spain, PCR was positive for evidence of TB in 77 percent of 72 specimens from 65 patients with EI (including 57 with positive tuberculin skin tests) [<a href="#rid26">26</a>]. In this series, there was a correlation between a positive test and the degree of tissue necrosis but not with any other histopathologic attributes [<a href="#rid26">26</a>]. In another study, multiplex PCR followed by nested PCR identified TB in tissue specimens from 8 of 10 patients considered to have TB-associated EI in Mexico City [<a href="#rid58">58</a>].</p><p>Reasonable additional initial tests for other associated diseases in patients without evidence of TB include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential </p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis C virus serology</p><p></p><p>The need for additional tests is guided by the findings on the review of symptoms. (See <a class="local">'Associated disorders'</a> above.)</p><p class="headingAnchor" id="H350698149"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for EI includes other forms of panniculitis that typically affect the lower extremities:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema nodosum</strong> – Erythema nodosum (EN) is the most common cause of primary panniculitis. Patients with EN typically present with nonulcerating bilateral nodules on the anterior legs (shins) rather than posterior legs. Considering the higher incidence of EN, nonclassic cases of EI are not infrequently clinically misdiagnosed as EN [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1">Pathologic findings that support EN include a mostly septal pattern of subcutaneous inflammation. Histiocytic aggregates surrounding clefts (Miescher's radial granuloma) are characteristic of EN. Similar to EI, EN is a reaction pattern with numerous possible disease associations including some that overlap with those of EI, including tuberculosis (TB) and possibly hepatitis C. (See  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious (infective) panniculitis</strong> – EI is characterized by neutrophilic granulomatous infiltrates, which is also the typical host response against most pathogens, particularly fungi, mycobacteria, and parasites. Since histochemical stains have limited sensitivity and negative stains do not exclude infection, lesional cultures and/or ancillary molecular diagnostic testing are required if infection is a clinical concern. For example, a case of panniculitis secondary to <em>Mycobacterium massiliense</em> was reported to mimic EI [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis", section on 'Infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous polyarteritis nodosa </strong>– Cutaneous polyarteritis nodosa (PAN) is characterized by tender, erythematous, purpuric macules, papules, and nodules, often occurring in a livedoid pattern on the lower extremities. Histologically, the changes in PAN are stereotypically centered upon small subcutaneous arteries, whereas prominent, extravascular, lobular subcutaneous inflammation affecting a wider range of vessel types is typical of EI. (See  <a class="medical medical_review" href="/z/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traumatic panniculitis</strong> – Similar to EI and infectious panniculitis, traumatic panniculitis presents as one or a few tender or asymptomatic nodule(s), usually on the lower extremities. Any site can be traumatized, the anterior leg (shin) being typical. Factitial panniculitis is regarded as a subset of traumatic panniculitis. Histologically, traumatic panniculitis shows prominent fat necrosis with lipophagic fat necrosis and lipomembranous fat necrosis predominating; vasculitis is not a feature.</p><p></p><p class="headingAnchor" id="H2102529138"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>EI is not a life-threatening disorder; however, treatment is usually given because EI can be painful and disfiguring  (<a class="graphic graphic_algorithm graphicRef109753" href="/z/d/graphic/109753.html" rel="external">algorithm 1</a>). In addition, untreated underlying diseases such as tuberculosis (TB) can cause death or significant morbidity. </p><p class="headingAnchor" id="H3837939342"><span class="h2">First-line treatment</span><span class="headingEndMark"> — </span>EI can be cured if the underlying cause is identified and successfully treated  (<a class="graphic graphic_algorithm graphicRef109753" href="/z/d/graphic/109753.html" rel="external">algorithm 1</a>). Patients with evidence for latent or active TB should receive standard treatment for TB in accordance with current guidelines. As with other tuberculids, TB-associated EI generally responds to anti-TB therapy. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p>In addition, nonsteroidal anti-inflammatory drugs, rest, elevation, and compression can be helpful for improving symptoms [<a href="#rid2">2,30</a>].</p><p>If an underlying disease cannot be identified and treated, management of EI can be challenging. (See <a class="local">'Other interventions'</a> below.)</p><p class="headingAnchor" id="H1498621311"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>Limited data from case reports and case series suggest that other interventions may be useful for idiopathic EI or EI that cannot be cured through treatment of an underlying disease. Oral potassium iodide is our preferred first-line treatment for these patients [<a href="#rid61">61</a>] and may result in remission [<a href="#rid62">62-64</a>]. In one series, 16 of 17 patients with non-TB-associated EI responded to potassium iodide (360 to 900 mg per day) [<a href="#rid62">62</a>]. Patients were generally treated for three to four weeks because shorter courses seemed to promote relapse. Decreased pain and swelling occurred within two days, and complete resolution occurred within four weeks. In another series, 7 of 10 patients with EI achieved resolution of symptoms within 24 hours and complete resolution of lesions within two weeks with potassium iodide (300 mg three times per day) [<a href="#rid64">64</a>]. In both series, recurrences responded to retreatment. </p><p>Treatment with potassium iodide is generally well tolerated. Long-term treatment is associated with risk for hypothyroidism. Other potential side effects of potassium iodide include gastrointestinal symptoms, salivary gland enlargement, and potassium toxicity. Given that a rapid response is expected, if there is no response within two to three weeks, treatment can be discontinued [<a href="#rid64">64</a>].</p><p>Other treatments have been suggested, including systemic glucocorticoids (provided infection has been ruled out) [<a href="#rid30">30</a>], <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> [<a href="#rid65">65</a>] or <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid18">18</a>] as a glucocorticoid-sparing agent, gold salts [<a href="#rid66">66</a>], <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [<a href="#rid67">67</a>], and topical anti-TB therapy [<a href="#rid68">68</a>]. However, evidence for benefit is limited to case reports. The efficacy of local therapies, such as topical or intralesional corticosteroids, is unclear. </p><p>Although some authors have suggested treatment with antituberculous drugs even in the absence of evidence for TB, given the potential side effects of antituberculous treatment, this is generally reserved for patients with evidence of latent or active TB [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2376643548"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognostic data have not been reported. As a reaction pattern, EI is a heterogeneous entity with a correspondingly variable clinical course. Successful treatment of an associated underlying disease usually leads to resolution, although relapsing disease in patients with TB-associated EI has been reported [<a href="#rid5">5</a>]. Idiopathic EI can progress for months to years but may eventually stabilize or remit in association with treatment such as potassium iodide.</p><p class="headingAnchor" id="H541639168"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Erythema induratum (EI) is an uncommon form of panniculitis that may occur in association with tuberculosis (most common), other diseases or drugs, or as an idiopathic condition. EI is regarded as an immune-mediated hypersensitivity reaction. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EI most frequently occurs in adult females but may also occur in males and children. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common clinical presentation of EI is single or multiple erythematous nodule(s) on the posterior or lateral lower legs  (<a class="graphic graphic_picture graphicRef76526 graphicRef64335 graphicRef53596 graphicRef110672" href="/z/d/graphic/76526.html" rel="external">picture 1A-D</a>). Thigh and upper extremity involvement occurs occasionally. Truncal, facial, or disseminated EI is rare. Ulceration of nodules is common. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of EI is made based upon the presence of consistent clinical and histologic findings. Skin biopsies demonstrate a predominantly lobular panniculitis with a mixed and granulomatous inflammatory infiltrate with vasculitis  (<a class="graphic graphic_picture graphicRef110673" href="/z/d/graphic/110673.html" rel="external">picture 2</a>). Multiple sections or multiple specimens may be required to identify vasculitis. (See <a class="local">'Histopathology'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the strong association of EI with tuberculosis, all patients with EI should be evaluated for tuberculosis. (See <a class="local">'Additional studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-line treatment for nonidiopathic EI is treatment of the underlying associated disease  (<a class="graphic graphic_algorithm graphicRef109753" href="/z/d/graphic/109753.html" rel="external">algorithm 1</a>). Nonsteroidal anti-inflammatory drugs, rest, elevation, and compression may aid with symptomatic improvement. (See <a class="local">'First-line treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When an underlying disease cannot be identified and treated, treatment may be challenging. Data on therapeutic options are limited. We suggest a trial of oral potassium iodide for these patients (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other treatments that may be beneficial include systemic glucocorticoids, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, gold salts, and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil. (See <a class="local">'Other interventions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">FEIWEL M, MUNRO DD. DIAGNOSIS AND TREATMENT OF ERYTHEMA INDURATUM (BAZIN). Br Med J 1965; 1:1109.</a></li><li><a class="nounderline abstract_t">Mascaró JM Jr, Baselga E. Erythema induratum of bazin. Dermatol Clin 2008; 26:439.</a></li><li><a class="nounderline abstract_t">Montgomery H, O'Leary PA, Barker NW. Nodular vascular diseases of the legs: Erythema induratum and allied conditions. JAMA 1945; 128:335.</a></li><li><a class="nounderline abstract_t">Rademaker M, Lowe DG, Munro DD. Erythema induratum (Bazin's disease). J Am Acad Dermatol 1989; 21:740.</a></li><li><a class="nounderline abstract_t">Ho CK, Ho MH, Chong LY. Cutaneous tuberculosis in Hong Kong: an update. Hong Kong Med J 2006; 12:272.</a></li><li><a class="nounderline abstract_t">Mann D, Sant'Anna FM, Schmaltz CAS, et al. Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases. Int J Dermatol 2019; 58:1451.</a></li><li><a class="nounderline abstract_t">Zhang J, Fan YK, Wang P, et al. Cutaneous tuberculosis in China - A multicentre retrospective study of cases diagnosed between 1957 and 2013. J Eur Acad Dermatol Venereol 2018; 32:632.</a></li><li><a class="nounderline abstract_t">Segura S, Pujol RM, Trindade F, Requena L. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients. J Am Acad Dermatol 2008; 59:839.</a></li><li><a class="nounderline abstract_t">Cho KH, Lee DY, Kim CW. Erythema induratum of Bazin. Int J Dermatol 1996; 35:802.</a></li><li><a class="nounderline abstract_t">Lighter J, Tse DB, Li Y, Borkowsky W. Erythema induratum of Bazin in a child: evidence for a cell-mediated hyper-response to Mycobacterium tuberculosis. Pediatr Infect Dis J 2009; 28:326.</a></li><li><a class="nounderline abstract_t">Chang MW, Lawrence R, Orlow SJ. Erythema induratum of Bazin in an infant. Pediatrics 1999; 103:498.</a></li><li><a class="nounderline abstract_t">Lee YS, Lee JH, Choi JE, et al. Erythema induratum of Bazin in a 10-year-old boy. Pediatr Dermatol 2021; 38:290.</a></li><li><a class="nounderline abstract_t">Sharon V, Goodarzi H, Chambers CJ, et al. Erythema induratum of Bazin. Dermatol Online J 2010; 16:1.</a></li><li><a class="nounderline abstract_t">Magalhães TS, Dammert VG, Samorano LP, et al. Erythema induratum of Bazin: Epidemiological, clinical and laboratorial profile of 54 patients. J Dermatol 2018; 45:628.</a></li><li><a class="nounderline abstract_t">Santos Felisberto V, Delgado AR, Pinto H, Morais P. Erythema Induratum of Bazin: A Case of Chronic Unilateral Erythematous Plaques in a Lower Limb. Isr Med Assoc J 2020; 11:720.</a></li><li><a class="nounderline abstract_t">Kara Polat A, Gore Karaali M, Esra Koku Aksu A, et al. A rare cutaneous tuberculosis form, erythema induratum of Bazin: 6 years' experience. Acta Dermatovenerol Alp Pannonica Adriat 2020; 29:123.</a></li><li><a class="nounderline abstract_t">Thoo CH, Graf N, Hogan P. Erythema induratum in a Kenyan child. Australas J Dermatol 2008; 49:156.</a></li><li><a class="nounderline abstract_t">Wee E, Kelly RI. Treatment of nodular vasculitis with colchicine. Australas J Dermatol 2017; 58:e79.</a></li><li><a class="nounderline abstract_t">Kwok CY, Goh CL, Ong BH. Retrospective study of the epidemiology of nodular vasculitis followed up in the National Skin Centre, Singapore. Clin Exp Dermatol 1997; 22:17.</a></li><li><a class="nounderline abstract_t">Koga T, Kubota Y, Kiryu H, et al. Erythema induratum in a patient with active tuberculosis of the axillary lymph node: IFN-gamma release of specific T cells. Eur J Dermatol 2001; 11:48.</a></li><li><a class="nounderline abstract_t">Teramura K, Fujimoto N, Nakanishi G, et al. Disseminated erythema induratum of Bazin. Eur J Dermatol 2014; 24:697.</a></li><li class="breakAll">James WD, Berger TG, Elston DM. Mycobacterial diseases. In: Andrews' Diseases of the Skin: Clinical Dermatology, 11th ed, Elsevier Saunders, 2011. p.328.</li><li><a class="nounderline abstract_t">Dharmadji HP, Suwarsa O, Sutedja E, et al. Erythema Induratum of Bazin Accompanied by Atrophy of the Subcutaneous Fat. Int Med Case Rep J 2021; 14:777.</a></li><li><a class="nounderline abstract_t">Silva MT, Antunes SL, Rolla VC, et al. Distal painful peripheral neuropathy associated with erythema induratum of Bazin. Eur J Neurol 2006; 13:e5.</a></li><li><a class="nounderline abstract_t">Zakeri K, Oganesyan G, Lee RA, Lillis JV. Erythema induratum of Bazin presenting as peripheral neuropathy. Cutis 2015; 96:E1.</a></li><li><a class="nounderline abstract_t">Baselga E, Margall N, Barnadas MA, et al. Detection of Mycobacterium tuberculosis DNA in lobular granulomatous panniculitis (erythema induratum-nodular vasculitis). Arch Dermatol 1997; 133:457.</a></li><li><a class="nounderline abstract_t">Roblin D, Kelly R, Wansbrough-Jones M, Harwood C. Papulonecrotic tuberculide and erythema induratum as presenting manifestations of tuberculosis. J Infect 1994; 28:193.</a></li><li><a class="nounderline abstract_t">Dongre AM, Sanghavi SA, Khopkar US. Papulonecrotic tuberculid at the site of tuberculin test in a patient with concomitant erythema induratum and papulonecrotic tuberculid. Indian J Dermatol Venereol Leprol 2013; 79:248.</a></li><li><a class="nounderline abstract_t">Kim GW, Park HJ, Kim HS, et al. Simultaneous occurrence of papulonecrotic tuberculid and erythema induratum in a patient with pulmonary tuberculosis. Pediatr Dermatol 2013; 30:256.</a></li><li><a class="nounderline abstract_t">Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther 2010; 23:320.</a></li><li><a class="nounderline abstract_t">Westers-Attema A, van Tubergen A, Plasschaert H, et al. Nodular vasculitis in systemic lupus erythematosus. Int J Dermatol 2008; 47 Suppl 1:3.</a></li><li><a class="nounderline abstract_t">Brandão Neto RA, Carvalho JF. Erythema induratum of Bazin associated with Addison's disease: first description. Sao Paulo Med J 2012; 130:405.</a></li><li><a class="nounderline abstract_t">Kabuto M, Nakanishi G, Kimura H, et al. Erythema induratum (nodular vasculitis) associated with Takayasu arteritis. Eur J Dermatol 2017; 27:410.</a></li><li><a class="nounderline abstract_t">Misago N, Narisawa Y. Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease. Am J Dermatopathol 2012; 34:325.</a></li><li><a class="nounderline abstract_t">Pozdnyakova O, Garg A, Mahalingam M. Nodular vasculitis - a novel cutaneous manifestation of autoimmune colitis. J Cutan Pathol 2008; 35:315.</a></li><li><a class="nounderline abstract_t">Khandpur S, Maharaja K. Inflammatory leg nodules: A clinical and investigational study. Natl Med J India 2016; 29:141.</a></li><li><a class="nounderline abstract_t">Pouldar D, Elsensohn A, Ortenzio F, et al. Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab. Am J Dermatopathol 2018; 40:e36.</a></li><li><a class="nounderline abstract_t">Oshio A, Yoshii Y, Ono K, et al. Erythema induratum of Bazin with anti-phospholipid antibodies. J Dtsch Dermatol Ges 2015; 13:810.</a></li><li><a class="nounderline abstract_t">Borges AS, Brasileiro A, Apetato M. Nodular vasculitis associated with lung adenocarcinoma. An Bras Dermatol 2018; 93:887.</a></li><li><a class="nounderline abstract_t">Fernandes SS, Carvalho J, Leite S, et al. Erythema induratum and chronic hepatitis C infection. J Clin Virol 2009; 44:333.</a></li><li><a class="nounderline abstract_t">Giménez-García R, Sánchez-Ramón S, Sánchez-Antolín G, Velasco Fernández C. Red fingers syndrome and recurrent panniculitis in a patient with chronic hepatitis C. J Eur Acad Dermatol Venereol 2003; 17:692.</a></li><li><a class="nounderline abstract_t">Sakuma H, Niiyama S, Amoh Y, Katsuoka K. Chlamydophila pneumoniae Infection Induced Nodular Vasculitis. Case Rep Dermatol 2011; 3:263.</a></li><li><a class="nounderline abstract_t">Campbell SM, Winkelmann RR, Sammons DL. Erythema Induratum Caused by Mycobacterium chelonei in an Immunocompetent Patient. J Clin Aesthet Dermatol 2013; 6:38.</a></li><li><a class="nounderline abstract_t">Hattori M, Shimizu A, Hisada T, et al. Erythema Induratum in a Patient with Pulmonary Mycobacterium avium Infection. Acta Derm Venereol 2016; 96:705.</a></li><li><a class="nounderline abstract_t">Romero JJ, Herrera P, Cartelle M, et al. Panniculitis caused by Mycobacterium monacense mimicking erythema induratum: a case in Ecuador. New Microbes New Infect 2016; 10:112.</a></li><li><a class="nounderline abstract_t">Park SB, Chang IK, Im M, et al. Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis. Ann Dermatol 2015; 27:605.</a></li><li><a class="nounderline abstract_t">Uesugi-Uchida S, Oyama N, Koizumi H, et al. Tuberculosis-unrelated erythema induratum occurring after commencing tumor necrosis factor (TNF)-α antagonist therapy in a case with ulcerative colitis: A rare comorbidity interconnected by TNF-α blockade pathway. J Dermatol 2020; 47:e326.</a></li><li><a class="nounderline abstract_t">Hamie L, Abbas O, Kanj-Sharara S, Abou Rahal J. Erythema induratum of Bazin after intravesical Bacillus Calmette-Guérin immunotherapy. Clin Exp Pharmacol Physiol 2022; 49:544.</a></li><li><a class="nounderline abstract_t">Wolf D, Ben-Yehuda A, Okon E, Naparstek Y. Nodular vasculitis associated with propylthiouracil therapy. Cutis 1992; 49:253.</a></li><li><a class="nounderline abstract_t">Baba N, Takashima W, Tokuriki A, et al. Erythema induratum of Bazin which occurred after tumor necrosis factor antagonist therapy. J Dermatol 2017; 44:e87.</a></li><li><a class="nounderline abstract_t">Vena GA, Apruzzi D, Vestita M, et al. Recurrence of erythema induratum of Bazin in a patient under chemotherapy for breast cancer. New Microbiol 2011; 34:331.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Fraga J, Sánchez-Schmidt JM, et al. Neutrophilic Infiltrates in Panniculitis: Comprehensive Review and Diagnostic Algorithm Proposal. Am J Dermatopathol 2020; 42:717.</a></li><li><a class="nounderline abstract_t">Friedman PC, Husain S, Grossman ME. Nodular tuberculid in a patient with HIV. J Am Acad Dermatol 2005; 53:S154.</a></li><li><a class="nounderline abstract_t">Jordaan HF, Schneider JW, Abdulla EA. Nodular tuberculid: a report of four patients. Pediatr Dermatol 2000; 17:183.</a></li><li><a class="nounderline abstract_t">Yi SM, Kim DH, Son SW, et al. Hidden tuberculous lymphadenitis and miliary tuberculosis in an erythema induratum patient: usefulness of interferon-γ release assays in the diagnosis. J Dermatol 2013; 40:1063.</a></li><li><a class="nounderline abstract_t">Sim JH, Whang KU. Application of the QuantiFERON®-TB Gold test in erythema induratum. J Dermatolog Treat 2014; 25:260.</a></li><li><a class="nounderline abstract_t">Schneider JW, Jordaan HF, Geiger DH, et al. Erythema induratum of Bazin. A clinicopathological study of 20 cases and detection of Mycobacterium tuberculosis DNA in skin lesions by polymerase chain reaction. Am J Dermatopathol 1995; 17:350.</a></li><li><a class="nounderline abstract_t">Maldonado-Bernal C, Ramos-Garibay A, Rios-Sarabia N, et al. Nested Polymerase Chain Reaction and Cutaneous Tuberculosis. Am J Dermatopathol 2019; 41:428.</a></li><li><a class="nounderline abstract_t">Khandpur S, Sethy PK, Sharma VK, Das P. An atypical presentation of erythema induratum. Indian J Dermatol Venereol Leprol 2008; 74:505.</a></li><li><a class="nounderline abstract_t">Park SH, Chae JK, Kim EJ, Park K. A case of panniculitis caused by Mycobacterium massiliense mimicking erythema induratum. Br J Dermatol 2015; 173:235.</a></li><li class="breakAll">Cusack CA, Fanelli M. Panniculitis. In: Treatment of Skin Disease, 4th ed, Lebwohl MG, Berth-Jones J, Heymann WR, Coulson I (Eds), Elsevier Saunders, 2014. p.526.</li><li><a class="nounderline abstract_t">Schulz EJ, Whiting DA. Treatment of erythema nodosum and nodular vasculitis with potassium iodide. Br J Dermatol 1976; 94:75.</a></li><li><a class="nounderline abstract_t">Horio T, Danno K, Okamoto H, et al. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol 1983; 9:77.</a></li><li><a class="nounderline abstract_t">Horio T, Imamura S, Danno K, Ofuji S. Potassium iodide in the treatment of erythema nodosum and nodular vasculitis. Arch Dermatol 1981; 117:29.</a></li><li><a class="nounderline abstract_t">Kieu V, Williams R, Hill P, Kelly R. Clofazimine-induced enteropathy in treatment-resistant nodular vasculitis. Australas J Dermatol 2012; 53:141.</a></li><li><a class="nounderline abstract_t">Shaffer N, Kerdel FA. Nodular vasculitis (erythema induratum): treatment with auranofin. J Am Acad Dermatol 1991; 25:426.</a></li><li><a class="nounderline abstract_t">Taverna JA, Radfar A, Pentland A, et al. Case reports: nodular vasculitis responsive to mycophenolate mofetil. J Drugs Dermatol 2006; 5:992.</a></li><li><a class="nounderline abstract_t">Mei X, Zhao J. Successful treatment of erythema induratum with topical application of antituberculous drugs: A case report. Medicine (Baltimore) 2017; 96:e9010.</a></li></ol></div><div id="topicVersionRevision">Topic 109264 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14270191" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : DIAGNOSIS AND TREATMENT OF ERYTHEMA INDURATUM (BAZIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18793975" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Erythema induratum of bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nodular vascular diseases of the legs: Erythema induratum and allied conditions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2808790" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Erythema induratum (Bazin's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912353" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous tuberculosis in Hong Kong: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31553059" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cutaneous tuberculosis in Rio de Janeiro, Brazil: description of a series of 75 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29476577" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cutaneous tuberculosis in China - A multicentre retrospective study of cases diagnosed between 1957 and 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19119100" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915735" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Erythema induratum of Bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19238114" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Erythema induratum of Bazin in a child: evidence for a cell-mediated hyper-response to Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925850" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Erythema induratum of Bazin in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33006145" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Erythema induratum of Bazin in a 10-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20409408" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Erythema induratum of Bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29696708" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Erythema induratum of Bazin: Epidemiological, clinical and laboratorial profile of 54 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33249795" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Erythema Induratum of Bazin: A Case of Chronic Unilateral Erythematous Plaques in a Lower Limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32975298" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A rare cutaneous tuberculosis form, erythema induratum of Bazin: 6 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18638224" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Erythema induratum in a Kenyan child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27245688" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of nodular vasculitis with colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330046" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Retrospective study of the epidemiology of nodular vasculitis followed up in the National Skin Centre, Singapore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174139" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erythema induratum in a patient with active tuberculosis of the axillary lymph node: IFN-gamma release of specific T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25333887" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Disseminated erythema induratum of Bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25333887" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Disseminated erythema induratum of Bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34815719" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Erythema Induratum of Bazin Accompanied by Atrophy of the Subcutaneous Fat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116205" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Distal painful peripheral neuropathy associated with erythema induratum of Bazin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26562274" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Erythema induratum of Bazin presenting as peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126009" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Detection of Mycobacterium tuberculosis DNA in lobular granulomatous panniculitis (erythema induratum-nodular vasculitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035000" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Papulonecrotic tuberculide and erythema induratum as presenting manifestations of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23442472" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Papulonecrotic tuberculid at the site of tuberculin test in a patient with concomitant erythema induratum and papulonecrotic tuberculid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22472030" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Simultaneous occurrence of papulonecrotic tuberculid and erythema induratum in a patient with pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666819" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986475" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nodular vasculitis in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23338738" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Erythema induratum of Bazin associated with Addison's disease: first description.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28470150" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Erythema induratum (nodular vasculitis) associated with Takayasu arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22172959" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18251747" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nodular vasculitis - a novel cutaneous manifestation of autoimmune colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27808062" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inflammatory leg nodules: A clinical and investigational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28953016" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26178638" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Erythema induratum of Bazin with anti-phospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484537" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nodular vasculitis associated with lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19233721" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Erythema induratum and chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14761140" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Red fingers syndrome and recurrent panniculitis in a patient with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22220148" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chlamydophila pneumoniae Infection Induced Nodular Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23710270" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Erythema Induratum Caused by Mycobacterium chelonei in an Immunocompetent Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26806446" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Erythema Induratum in a Patient with Pulmonary Mycobacterium avium Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933504" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Panniculitis caused by Mycobacterium monacense mimicking erythema induratum: a case in Ecuador.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26512176" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32686155" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tuberculosis-unrelated erythema induratum occurring after commencing tumor necrosis factor (TNF)-αantagonist therapy in a case with ulcerative colitis: A rare comorbidity interconnected by TNF-αblockade pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35119123" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Erythema induratum of Bazin after intravesical Bacillus Calmette-Guérin immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1521477" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nodular vasculitis associated with propylthiouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28106269" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Erythema induratum of Bazin which occurred after tumor necrosis factor antagonist therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21811756" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recurrence of erythema induratum of Bazin in a patient under chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956080" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Neutrophilic Infiltrates in Panniculitis: Comprehensive Review and Diagnostic Algorithm Proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021168" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nodular tuberculid in a patient with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886748" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nodular tuberculid: a report of four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330178" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hidden tuberculous lymphadenitis and miliary tuberculosis in an erythema induratum patient: usefulness of interferon-γrelease assays in the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920648" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Application of the QuantiFERON®-TB Gold test in erythema induratum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600798" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Erythema induratum of Bazin. A clinicopathological study of 20 cases and detection of Mycobacterium tuberculosis DNA in skin lesions by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531542" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nested Polymerase Chain Reaction and Cutaneous Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052421" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : An atypical presentation of erythema induratum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25494865" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A case of panniculitis caused by Mycobacterium massiliense mimicking erythema induratum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25494865" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A case of panniculitis caused by Mycobacterium massiliense mimicking erythema induratum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/943168" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of erythema nodosum and nodular vasculitis with potassium iodide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886108" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Potassium iodide in erythema nodosum and other erythematous dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7458376" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Potassium iodide in the treatment of erythema nodosum and nodular vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571566" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clofazimine-induced enteropathy in treatment-resistant nodular vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894786" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nodular vasculitis (erythema induratum): treatment with auranofin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17373149" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Case reports: nodular vasculitis responsive to mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29245283" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful treatment of erythema induratum with topical application of antituberculous drugs: A case report.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
